Tech Company Financing Transactions
Veradermics Funding Round
SR One Capital Management, Columbia Threadneedle Investments and Invus participated in a $150 million Series C funding round for Veradermics. The round was announced on 10/16/2025.
Transaction Overview
Company Name
Announced On
10/16/2025
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing are intended to advance and complete the ongoing Phase 3 trials and, if the clinical data are supportive, a subsequent New Drug Application ("NDA") submission to the U.S. Food and Drug Administration ("FDA") for VDPHL01.
Company Information
Company Status
Private & Independent
Industry
Software
Mailing Address
470 James St
New Haven, CT 06470
USA
New Haven, CT 06470
USA
Phone
Undisclosed
Website
Email Address
Overview
Founded by dermatologists, the company is leveraging its executive team's proven front-line clinical experience to identify and develop innovative therapeutics that address specific patient needs and solve pervasive treatment challenges in dermatology practice. Guided by a steadfast commitment to tackling real-world patient and clinician problems that limit the current standard of care for common skin conditions, Veradermics is acting with urgency to advance a pipeline of diverse, first-in-class, product candidates with demonstrated mechanisms of action.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/16/2025: Upgrade venture capital transaction
Next: 10/16/2025: OneLayer venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








